Clinical validation of MYND Diagnostics’ proprietary biomarkers in evaluating the efficacy of psilocybin-assisted psychotherapy in treatment-resistant depression VANCOUVER, BC, Feb. 8, 2022 /CNW/ – MYND Diagnostics Inc., a wholly-owned subsidiary of MYND Life Sciences (CSE: MYND) (OTC: MYNDF), is pleased to announce that the Company’s proprietary biomarker testing technology will be a pivotal…
